StreetAlpha.app
Home › Stocks › ANNX

Annexon, Inc. (ANNX)

Healthcare
$3.10
▼ −9.09%
LAST CLOSE · NOV 20

Annexon is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases of the body, brain and eye. It last closed at $3.10 on Nov 20, down 9.09% on the day. The next earnings report for ANNX is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, ANNX reported EPS of -$0.25. Over its last 8 reports the stock moved an average of 2.8% the session after earnings. Over the last 12 months ANNX insiders bought $7.5M of stock on the open market and sold $313K, according to SEC Form 4 filings.

AI Auto Pilots
Is ANNX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANNX.

Key Stats

Last 12 months
Results
Net income
−$199.0M
EPS (diluted)
−$1.01
Free cash flow
−$189.5M
Balance sheet
Cash & equivalents
$102.4M
At Sep 30
Debt
$49.3M
At Sep 30
Shareholder equity
$142.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$130.3M−$130.3MFY2021FY2022: −$141.9M−$141.9MFY2022FY2023: −$134.2M−$134.2MFY2023FY2024: −$138.2M−$138.2MFY2024FY2025: −$206.7M−$206.7MFY2025

From ANNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · After the close
Reported EPS
-$0.25
Quarter ended Sep 2026
Year ago EPS
-$0.37
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.33Dec '24Mar 2025: -$0.37Mar '25Jun 2025: -$0.34Jun '25Sep 2025: -$0.37Sep '25Dec 2025: -$0.26Dec '25Mar 2026: -$0.23Mar '26Jun 2026: -$0.28Jun '26Sep 2026: -$0.25Sep '26Latest -$0.25
Revenue by quarter
Not enough quarters on file yet.
How ANNX moved after its last 8 reports
Average move the session after a report ±2.8%
Nov 9, 2026After the close−0.5%
Aug 12, 2026Time not announced−0.2%
May 7, 2026After the close+3.1%
Mar 30, 2026After the close+11.7%
Nov 10, 2025After the close−0.3%
Aug 14, 2025After the close+2.5%
May 12, 2025After the close−1.1%
Mar 3, 2025After the close+3.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ANNXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANNX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANNX

Technical Analysis

ANNX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 26% below its 20 day and 27% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $3.07, and the nearest resistance the Pivot at $3.18.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.9%/day
Key levels
$7.1852 week high+131.6%
$5.03200 day average+62.3%
$4.60100 day average+48.4%
$4.07Swing high (Oct 21)+31.3%
$3.9350 day average+26.8%
$3.8920 day average+25.5%
$3.29Pivot R1+6.1%
$3.18Pivot+2.6%
$3.10Last close
$3.0752 week low−1.0%
$2.99Pivot S1−3.5%
Indicators
RSI (14)29.68Oversold below 30Oversold
MACD-0.16Below its signal lineBearish
Stochastic6.5Near the bottom of its rangeOversold
ADX (14)20.1Weak trend
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-196.6Oversold below −100, overbought above 100Oversold
Rate of change−26.2%Change over 10 sessionsBearish
ATR (14)$0.27Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANNX

What happened before

See how ANNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ANNX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANNXHow many large options trades hit ANNX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ANNX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●112 buying vs 98 selling
  • ▲Shares held by funds +10.1%
  • ▼Funds holding -10
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding207217−4.6%
In funds' top 10440.0%
Held by funds–––
New / increased31 / 8129 / 78+4.7%
Reduced / sold out58 / 4079 / 28−8.4%
Put/call ratio0.680.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANNX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANNX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$7.5M10 buys · 4 insiders
Sold$313K10 sales · 5 insiders
Cluster buy: 2 insiders bought $3.4M between May 11 and May 28.
2025-12 bought $177K2026-02 sold $166K2026-03 bought $45K2026-03 sold $147K2026-04 bought $50K2026-05 bought $3.4M2026-09 bought $100K2026-11 bought $122KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19William H. CarsonDirectorBuy34,000$3.58$122K
Sep 24Douglas LovePresident And CEOBuy26,065$3.83$100K
May 28Muneer A SatterDirectorBuy613,497$5.41$3.3M
May 11William H. CarsonDirectorBuy8,000$5.78$46K
Apr 10William H. CarsonDirectorBuy8,000$6.20$50K
Mar 10William H. CarsonDirectorBuy8,000$5.67$45K
Every insider buy and sale for ANNX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANNX insider trades →

From SEC Form 4 filings by ANNX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANNX is in one of them and how their past ANNX trades turned out.

ANNX in the AI portfolios
Loading…

ANNX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANNX in an article yet. Here's the latest on the wider market.

ANNX in the news

About Annexon

Annexon is a biopharmaceutical company based in Brisbane, California. It develops drug candidates that target C1q, an early step in the classical complement pathway, a part of the immune system that can drive inflammation and tissue damage. Its main programs address neuroinflammatory diseases of the body, brain and eye, including Guillain-Barré Syndrome, geographic atrophy and autoimmune conditions. The company is developing these treatments for patients and does not yet have an approved product.

Headquarters
Brisbane, CA